Parkinson’s Disease / 2014 / Article / Tab 1

Clinical Study

Parkinson’s Disease: Low-Dose Haloperidol Increases Dopamine Receptor Sensitivity and Clinical Response

Table 1

Patient data.

SubjectAgeM/FDisease duration, yearsSCOPA baseline at week 1MedicationL-DOPA dose/day

10170M114Sinemet 100/25, 3/day300 mg
10259F225Levocarb 100/25, 1 qhs prn; Stalevo 150/37.5; 5/day850 mg
10381F3142Sinemet cr 100/25, 5/day; Sinemet 100, 1/day600 mg
10480M926Levocarb 100/10 2 tabs, 5/day1000 mg
10576M1023Pramipexole 200 mg, 3/day=600 mg
10670M1229Apo-Levocarb 100/25, 3 tabs, 4/day1200 mg
10781M420Apo-Levocarb 25 mg, 3/day300 mg
10865M1027None0 mg
10961M316Levocarb 25 mg, 4/day100 mg
11067M816Levocarb 250/25 mg, 4/day; pramipexole 1 mg/day1000 mg
11272M630Apo-Levocarb 25 mg, 4/day100 mg
11361M621Sinemet, 100/25, 3/day300 mg
11463M1228Sinemet 100/25, 2 tabs, 5/day1000 mg
11577F730Sinemet 100/25700 mg
11792M1513Sinemet cr 100/50, 2/day200 mg
11880M517Apo-Levocarb 100/25, 1/day100 mg

Average728.823.6
s.e.1.9

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.